Moran Timothy P, Burks A Wesley
Department of Pediatrics, The University of North Carolina School of Medicine, 104 Mason Farm Road Campus, Box 7310, Chapel Hill, NC, 27599-7310, USA,
Curr Allergy Asthma Rep. 2015 May;15(5):23. doi: 10.1007/s11882-015-0523-3.
There is a growing evidence that allergen immunotherapy (AIT) can provide significant and long-lasting clinical benefit for a number of allergic individuals. However, it is less clear if AIT results in clinical tolerance, which is characterized by a persistent state of clinical non-reactivity to allergens after therapy is finished. Addressing this knowledge gap is particularly relevant for patients undergoing AIT for food allergies, as anything less than complete tolerance could have potentially devastating consequences. An increasing number of studies, in particular those involving oral immunotherapy, are attempting to assess tolerance induction following AIT. Clinical tolerance does appear to be achievable in a subset of patients undergoing AIT, but whether this is equivalent to the type of tolerance observed in nonallergic individuals remains unknown. Developing established criteria for assessing tolerance induction, as well as the use of consistent terminology when describing clinical tolerance, will be important for determining the disease-modifying potential of AIT.
越来越多的证据表明,变应原免疫疗法(AIT)能为许多过敏个体带来显著且持久的临床益处。然而,AIT是否会导致临床耐受尚不清楚,临床耐受的特征是在治疗结束后对变应原持续处于临床无反应状态。解决这一知识空白对于接受食物过敏AIT治疗的患者尤为重要,因为不完全耐受可能会带来潜在的灾难性后果。越来越多的研究,尤其是那些涉及口服免疫疗法的研究,正在尝试评估AIT后的耐受诱导情况。在接受AIT的一部分患者中似乎确实可以实现临床耐受,但这是否等同于在非过敏个体中观察到的耐受类型仍不清楚。制定评估耐受诱导的既定标准,以及在描述临床耐受时使用一致的术语,对于确定AIT改变疾病的潜力将至关重要。